Source:http://linkedlifedata.com/resource/pubmed/id/17972507
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5B
|
pubmed:dateCreated |
2007-11-1
|
pubmed:abstractText |
The aim of this retrospective study was to compare concurrent radiation therapy (RT) combined with peroral chemotherapy (UFT or TS-1) with conventional RT for T2N0 glottic cancer. Between 1974 and 2005, 153 patients with T2N0 glottic cancer were treated with radiation alone or radiation combined with peroral (UFT or TS-1) or intravenous chemotherapy. All except one patient were treated with 2 Gy per fraction, 5 fractions per week, totaling 60 Gy; and the remaining patient was treated with 1.8 Gy per fraction, 5 fractions per week, totaling 61.2 Gy. Eighty-three patients were concurrently given UFT, 24 were given TS-1, 23 intravenous chemotherapy (mainly cisplatin; the Pt Group), and 23 had no chemotherapy. The 5-year local control rate was 83.4%. Stratified by RT alone (the RT group) and concurrent chemoradiation therapy (the CCRT group), 5-year local control rates of the RT and CCRT groups were 82.7% and 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of the CCRT group, 3-year local control rates of the UFT, TS-1 and Pt groups were 90.1%, 100.0% and 73.4%, respectively. Concurrent chemoradiation therapy using UFT or TS-1 for T2N0 glottic cancer is one of the standard treatments in Japan. Concurrent use of TS-1 could be a breakthrough treatment for T2N0 glottic cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Silicates,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/Titanium,
http://linkedlifedata.com/resource/pubmed/chemical/titanium silicide
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3497-500
|
pubmed:meshHeading |
pubmed-meshheading:17972507-Aged,
pubmed-meshheading:17972507-Aged, 80 and over,
pubmed-meshheading:17972507-Antineoplastic Agents,
pubmed-meshheading:17972507-Combined Modality Therapy,
pubmed-meshheading:17972507-Female,
pubmed-meshheading:17972507-Humans,
pubmed-meshheading:17972507-Japan,
pubmed-meshheading:17972507-Laryngeal Neoplasms,
pubmed-meshheading:17972507-Male,
pubmed-meshheading:17972507-Middle Aged,
pubmed-meshheading:17972507-Retrospective Studies,
pubmed-meshheading:17972507-Silicates,
pubmed-meshheading:17972507-Survival Analysis,
pubmed-meshheading:17972507-Tegafur,
pubmed-meshheading:17972507-Titanium
|
pubmed:articleTitle |
Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.
|
pubmed:affiliation |
Department of Radiology, Kitasato University School of Medicine, Kanagawa, Japan. joe-n@hkg.odn.ne.jp
|
pubmed:publicationType |
Journal Article
|